Monte Rosa (GLUE) news

Orora: For SaveGlass, ongoing impacts from US tariffs, accelerated effects of Middle East conflict resulted in adverse price and mix effects in 2H26

Orora has reported adverse price and mix effects in the second half of 2026, primarily attributed to ongoing impacts from U.S. tariffs and the accelerated effects of the Middle East conflict. These factors have disrupted supply chains and altered market dynamics, particularly in the glass…

Thales: BofA global research raises price objective to EUR 315 from EUR 312

Bank of America Global Research has raised its price target for Thales (HO.PA) to EUR 315 from EUR 312, reflecting a more optimistic outlook for the French industrial conglomerate. This adjustment follows a prior increase in the target from EUR 303 to EUR 312, as reported earlier in October 2026.…

Monte Rosa Therapeutics shares up 2% after H.C. Wainwright initiates coverage with buy rating

Monte Rosa Therapeutics (GLUE) shares rose 2% following an initiation of coverage by H.C. Wainwright, which assigned the stock a "Buy" rating. The move comes amid ongoing investor interest in the biopharmaceutical company, which has market capitalization of $1.04 billion and an enterprise value of…

Monte Rosa Therapeutics announces positive results for MRT-8102

Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE) has outlined key developments in its clinical-stage pipeline for MRT-8102, a molecular glue degrader (MGD) being investigated for its potential to modulate sterile inflammation in multiple disease areas. The company recently completed enrollment and…

Monte Rosa Therapeutics, - To initiate multiple phase 2 studies of MRT-8102 in high unmet need indications